Health Care & Life Sciences » Biotechnology | Mirati Therapeutics Inc.

Mirati Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
62,148.00
29,303.00
122,327.00
56,734.00
150,837.00
222,790
Total Accounts Receivable
364.00
905.00
237.00
183.00
237.00
768
Other Current Assets
1,703.00
2,449.00
2,838.00
2,638.00
4,685.00
3,102
Total Current Assets
64,215.00
32,657.00
125,402.00
59,555.00
155,759.00
226,660
Net Property, Plant & Equipment
322.00
496.00
614.00
629.00
525.00
473
Total Investments and Advances
-
-
-
3,260.00
962.00
1,321
Other Assets
-
326.00
2,001.00
-
-
-
Total Assets
64,537.00
33,479.00
128,017.00
63,444.00
157,246.00
228,454
Accounts Payable
1,302.00
-
-
-
-
Other Current Liabilities
37,350.00
5,396.00
9,798.00
15,002.00
13,644.00
Total Current Liabilities
38,652.00
5,396.00
9,798.00
15,002.00
13,644.00
Other Liabilities
-
21.00
43.00
133.00
314.00
Total Liabilities
38,652.00
5,417.00
9,841.00
15,135.00
13,958.00
Common Equity (Total)
25,885.00
28,062.00
118,176.00
48,309.00
143,288.00
Total Shareholders' Equity
25,885.00
28,062.00
118,176.00
48,309.00
143,288.00
Total Equity
25,885.00
28,062.00
118,176.00
48,309.00
143,288.00
Liabilities & Shareholders' Equity
64,537.00
33,479.00
128,017.00
63,444.00
157,246.00

About Mirati Therapeutics

View Profile
Address
9393 Towne Centre Drive
San Diego California 92121
United States
Employees -
Website http://www.mirati.com
Updated 07/08/2019
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.